Navigation Links
NIH study reveals new genetic culprit in deadly skin cancer
Date:8/31/2009

ts' tumors, making it by far the most frequently mutated PTK gene in melanoma. In addition, researchers found that many ERBB4 mutations were located in functionally important areas similar to those seen in other PTK oncogenes involved in lung cancer, brain cancer and gastric cancer.

Next, the researchers moved on to laboratory studies of melanoma cells with ERBB4 mutations. They found that these melanoma cells were dependent on the presence of mutant ERBB4 for their growth. What's more, the melanoma cells grew much more slowly when they were exposed to a chemotherapeutic drug known to inhibit ERBB4. The drug, called lapatinib (Tykerb), was approved by the Food and Drug Administration in 2007 for combination use in breast cancer patients already taking the drug capecitabine (Xeloda).

Encouraged by their study results, the researchers are planning a clinical trial using lapatinib in patients with metastatic melanoma harboring ERBB4 mutations. The clinical trial will be conducted under the direction of Dr. Rosenberg at the NIH Clinical Center. "This collaborative study represents an ideal example of how sophisticated genetic analyses can be translated to the benefit of cancer patients," said Dr. Rosenberg.

"We have found what appears to be an Achilles' heel of a sizable share of melanomas," said Dr. Samuels, who is an investigator in the Cancer Genetics Branch of the NHGRI's Division of Intramural Research. "Though additional work is needed to gain a more complete understanding of these genetic mutations and their roles in cancer biology, our findings open the door to pursuing specific therapies that may prove useful for the treatment of melanoma with ERBB4 mutations."

In addition to ERBB4, the researchers identified two additional PTK genes, FLT1 and PTK2B, with a relatively high rate of mutations in melanoma. Each of these genes was mutated in about 10 percent of the tumor samples studied.

NHGRI Scientific Director Eric
'/>"/>

Contact: Geoffrey Spencer
spencerg@mail.nih.gov
301-402-0911
NIH/National Human Genome Research Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... (PRWEB) September 17, 2014 Recently, BamboofloorChina.com, ... added a new assortment of strand woven bamboo ... it has launched a big promotion for the new ... off. , Autumn is a great shopping season. ... items for old and new customers. All practical items ...
(Date:9/16/2014)... A nice seat cover is necessary for those who want ... offered by Lseat.com have every item clients need to completely ... protected from everyday wear and tear. , Today, the ... seat covers and launched an autumn special offer. All ... fabric that is both washable and breathable. That brings a ...
(Date:9/16/2014)... Marybeth Cale, owner of Cale Communications , ... in the small village of Rhinebeck, New York, has announced ... a mompreneur, has expanded the business to incorporate a new ... maximize potential. Those services will include group trainings and workshops ... coaching for clients all over the country. , Workshops ...
(Date:9/16/2014)... Retinol is favored by a majority of dermatologists ... has so many benefits - it is one of those ... Sublime Beauty . "Healthy skin is our goal, and ... Beauty® Retinol Serum with Vitamin C is a non-irritating, silky ... The Retinol Serum with Vitamin C is now ...
(Date:9/16/2014)... 2014 Operation Smile was founded “on the ... a facial deformity.” To spread their message and mission, the ... at the Beverly Wilshire Hotel in Beverly Hills, California. The ... whose lives have been forever transformed by the efforts of ... with Operation Smile,” said Lynda Erkiletian, Executive Director of The ...
Breaking Medicine News(10 mins):Health News:BamboofloorChina.com Announces Its Promotion For Strand Woven Bamboo Floors 2Health News:Lseat.com: 2006-2014 Chevrolet Tahoe Chevrolet Tahoe Leather Seat Covers At Discounted Rates 2Health News:Mompreneur Marybeth Cale of Cale Communications Announces Launch Of Life Coaching And Workshop Business 2Health News:Retinol, the Gold Standard in Skin Care, Available in a Serum with Vitamin C from Sublime Beauty®; Now 30% Off 2Health News:James & Paula Coburn Foundation to Host the 2014 Smile Gala, Presented by Operation Smile 2
... 10-30 minutes a day showed significant improvement in social ... Just 10 minutes to 30 minutes of exercise a ... overweight or obese women, American researchers suggest. , ... who took part in the Dose Response to Exercise ...
... can modestly increase the amount of physical activity among ... the Trial of Activity for Adolescent Girls (TAAG), a ... Heart, Lung, and Blood Institute (NHLBI) of the National ... the article, "Promoting Physical Activity in Middle School Girls," ...
... picture of events that underlie the functions of a ... by Cell Press in the journal Molecular Cell, shows ... clock keeps time and may enhance our understanding of ... , A variety of organisms have evolved endogenous timing ...
... 13 Cuyahoga Community College will,celebrate the grand opening ... from 9 a.m. -- noon at the Western Campus, ... -- 9:45 a.m. in the HTC,and building tours will ... 25,000-square-feet, the new Health Technologies Center,includes four classrooms, six ...
... outreach efforts, experts say , , THURSDAY, March 13 (HealthDay ... warning signs of eye diseases that could blind them ... survey shows. , The telephone survey, released Thursday by ... International Foundation, included interviews conducted with 3,000 adults between ...
... -,Best of Show, award winners and ,New and Notables, announced at the ... Aesthetics ... Conference and Expo-, LOS ANGELES, March 13 An ... Los Angeles Spa & Resort,Expo and Conference and Medical Aesthetics Conference and ...
Cached Medicine News:Health News:Minimal Exercise Benefits Overweight Postmenopausal Women 2Health News:After-school programs can increase physical activity of adolescent girls 2Health News:New research provides dynamic visualization of simplest circadian clock 2Health News:Tri-C to Celebrate Health Technologies Center Grand Opening April 4 2Health News:Survey Finds Many Americans Clueless About Eye Disease 2Health News:'Best of Show' Awards Go to Spa and Medical Aesthetics Industry Stars 2Health News:'Best of Show' Awards Go to Spa and Medical Aesthetics Industry Stars 3Health News:'Best of Show' Awards Go to Spa and Medical Aesthetics Industry Stars 4Health News:'Best of Show' Awards Go to Spa and Medical Aesthetics Industry Stars 5
(Date:9/16/2014)... , Sept. 16, 2014 Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... product to receive formal designation as a "Promising Innovative ... Scheme" (EAMS) launched in the UK in April 2014. ... process for early access approval under the EAMS.  ...
(Date:9/16/2014)... CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... and restatement of its outstanding Series C-2, C-3, ... as well as the warrants issued in its ... remove anti-dilution, price reset and certain change of ...
(Date:9/16/2014)... 16, 2014 Imprimis Pharmaceuticals, Inc. (Nasdaq: ... delivering high quality and novel medicines to physicians and ... Officer Mark Baum will be a presenter ... Conference in New York City.  Mr. Baum will discuss ... campaign in ophthalmology. The presentation is scheduled for 10:40 ...
Breaking Medicine Technology:NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4
... Pharmaceuticals, Inc. (NYSE Amex: INO ), a ... against cancers and infectious diseases, announced today the publication ... Vaccines detailing potent immune responses in a preclinical ... targeting two antigens. While current prostate cancer therapies target ...
... Feb. 1, 2011 Anthera Pharmaceuticals, Inc. (Nasdaq: ... treat serious diseases associated with abnormal auto-immune responses and ... Thompson to its Board of Directors. Currently, Dr. Thompson ... founder and Managing Director of Strategicon Partners, an investment ...
Cached Medicine Technology:Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 2Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 3Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 4Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 5Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors 2
Castroviejo "HM" Micro Needle Holder with Tungsten-Carbide Inserts, with catch. Serrated....
Curved with catch....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Medium weight bone cutter....
Medicine Products: